Articles By Rob Wright, Chief Editor 2011-2021
-
![handholdinghomehouse]( "Working From Home While Living In A Coronavirus World")
Working From Home While Living In A Coronavirus World3/13/2020Chief editor Rob Wright shares thoughts and best practices on working from home while living in a coronavirus world.
-
![Coronavirus Conference Cancellations]( "Pandemic’s Postponement Of 2020 R&D Leadership Summit Proves One Of Many")
Pandemic’s Postponement Of 2020 R&D Leadership Summit Proves One Of Many3/10/2020Chief Editor Rob Wright talks about the cancellation of the R&D Leadership Summit and why the U.S. holds the potential to be a coronavirus catastrophe.
-
![Life SCi Cares_Rob Perez_450x300]( "How Biopharma Came Together To Impact Poverty In Boston")
How Biopharma Came Together To Impact Poverty In Boston2/28/2020Life science cares aims to eliminate the impact of poverty in Boston, and it’s now spreading to other parts of the country.
-
![Feature - Blueprint_450x300]( "Jeff Albers’ Blueprint For Blueprint Medicines")
Jeff Albers’ Blueprint For Blueprint Medicines2/28/2020Jeff Albers, president and CEO of Blueprint Medicines, discusses his approach to ensuring the biopharma is commercial ready should it garner some pivotal FDA approvals.
-
![Leadership_Rob Wright2019_450x300]( "Do You Make Your Own Luck?")
Do You Make Your Own Luck?2/28/2020“The only thing “lucky” was my having the opportunity to learn from someone who continues to make their own luck.”
-
![Rob Wright 2017]( "Dear Readers — We Hear You")
Dear Readers — We Hear You2/28/2020Chief editor Rob Wright talks about reader feedback on the diversity of our covers as well as why one reader prefers to read our magazine in print as compared to online.
-
![Carol Lynch 1 BIO CEO 2020]( "BIO CEO 2020 Is No JPM — And That’s A Good Thing")
BIO CEO 2020 Is No JPM — And That’s A Good Thing2/14/2020Chief editor Rob Wright provides an overview of some of his experiences from recent attendance at the BIO CEO and Investor Conference in New York.
-
![Feature - Allogene_450x300]( "Allogene Therapeutics — The Juggernaut Built On Kite’s Flight")
Allogene Therapeutics — The Juggernaut Built On Kite’s Flight1/31/2020David Chang, M.D., Ph.D., CEO and cofounder of Allogene Therapeutics, shares how the successful exit from Kite Pharma (acquired by Gilead for $11.9 billion in 2017) led to the building of Allogene, a $3.4 billion clinical-stage biopharma developing allogeneic CAR-T therapy.
-
![JohnSculley_450x300]( "Why John Sculley Views Healthcare As His “Noble Cause”")
Why John Sculley Views Healthcare As His “Noble Cause”1/31/2020John Sculley, the former CEO of Apple who is now an entrepreneur and investor in high-tech startups, discusses where he sees opportunity in the healthcare industry, along with the leaders he views as being just as visionary as Steve Jobs, if not more so.
Rob Wright
Rob Wright was chief editor of Life Science Leader magazine from 2011-2021. Prior to joining the publication, he spent nearly 20 years in the pharmaceutical industry. During his industry career, Wright conducted well over 1,000 presentations and roundtable discussions, including the facilitation of FDA-mandated clinical training programs for hundreds of licensed healthcare providers. He has chaired, moderated, and served as a speaker at industry and academic conferences, and served as co-chair for the 2015 and 2018 BIO International conference’s educational planning committee. Wright’s 500+ published articles have appeared in peer-reviewed academic journals, B2B magazines and online publications. He received a B.S. in Business Administration from Indiana University of Pennsylvania, MBA with distinction from Gannon University, and completed his doctoral coursework in marketing at Cleveland State University. He is a member of international business honor societies Sigma Beta Delta and Beta Gamma Sigma. He can be followed on Twitter @RfwrightLSL